Intravitreal bevacizumab (Avastin) in the treatment of macular edema associated with perfused retinal vein occlusion

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 85-90

  Hung, Kuo Hsuan ^a   Lee, Shui Mei ^a   Lee, Shih Yun ^a   Lee, Feng Lih ^a   Yang, Chang Sue ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID; FLUORESCEIN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CARDIOVASCULAR DISEASE; CASE STUDY; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PARAMETER; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; SLIT LAMP; THROMBOEMBOLISM; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77649334527     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0090     Document Type: Article

References (27)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular oedema in branch vein occlusion. Am. J. Ophthalmol. 98:271-282, 1984.
2. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology. 102:1425-1433, 1995.
3. Bashshur, Z.F., Ma'luf, R.N., Allam, S., et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch. Ophthalmol. 122:1137-1140, 2004.
4. Shulman, S., Ferencz, J.R., Gilady, G., et al. Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Eye. 21:1067-1070, 2007.
5. Thompson, J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol. 141:629-637, 2006.
6. Nagpal, M., Nagpal, K., Bhatt, C., et al. Role of early radial optic neurotomy in central retinal vein occlusion. Indian J. Ophthalmol. 53:115-120, 2005.
7. Tang, W.M., and Han, D.P. A study of surgical approaches to retinal vascular occlusions. Arch Ophthalmol. 118:138-143, 2000.
8. Noma, H., Funatsu, H., Yamasaki, M., et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140:256-261, 2005.
9. Noma, H., Minamoto, A., Funatsu, H., et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 244:309-315, 2006.
10. Pe'er, J., Folberg, R., Itin, A., et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 105:412-416, 1998.
11. Rosenfeld, P.J., Fung, A.E., and Puliafi to, C.A. Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg. Lasers Imaging. 36:336-339, 2005.
12. Costa, R.A., Jorge, R., Calucci, D., et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 27:141-149, 2007.
13. Schaal, K.B., Höh, A.E., Scheuerle, A., et al. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe. 104:285-289, 2007.
14. Pai, S.A., Shetty, R., Vijayan, P.B., et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am. J. Ophthalmol. 143:601-606, 2007.
15. Rabena, M.D., Pieramici, D.J., Castellarin, A.A., et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 27:419-425, 2007.
16. Kriechbaun, K., Michels, S., Prager, F., et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol. 92:518-522, 2008.
17. Keck, P.J., Hauser, S.D., Krivi, G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1309-1312, 1989.
18. Leung, D.W., Cachianes, G., Kuang, W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306-1309, 1989.
19. Senger, D.R., Connolly, D.T., Van de Water, L., et al. Purifi cation and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50:1774-1778, 1990.
20. Antonetti, D.A., Barber, A.J., Hollinger, L.A., et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J. Biol. Chem. 274:23463-23467, 1999.
21. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113:363-372, 2006.
22. Central Retinal Vein Occlusion. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 115:486-491, 1997.
23. Stahl, A., Agostini, H., Hansen, L.L., et al. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch. Clin. Exp. Ophthalmol. 245:1429-1436, 2007.
24. Matsumoto, Y., Freund, K.B., Peiretti, E., et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 27:426-431, 2007.
25. Noma, H., Funatsu, H., Yamasaki, M., et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye. 22:42-48, 2008.
26. Noma, H., Funatsu, H., Mimura, T., et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 116:87-93, 2009.
27. Wu, L., Arevalo, J.F., Roca, J.A., et al.; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 28:212-219, 2008.